These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 39489506)

  • 1. Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network.
    Zirpel H; Ludwig RJ; Olbrich H; Kridin K; Ständer S; Thaçi D
    J Dermatolog Treat; 2024 Dec; 35(1):2421429. PubMed ID: 39489506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy.
    Gori N; Chiricozzi A; Malvaso D; D'Urso DF; Caldarola G; De Simone C; Peris K
    Dermatology; 2021; 237(4):535-541. PubMed ID: 33477153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic treatments for eczema: a network meta-analysis.
    Sawangjit R; Dilokthornsakul P; Lloyd-Lavery A; Lai NM; Dellavalle R; Chaiyakunapruk N
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD013206. PubMed ID: 32927498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis.
    Drucker AM; Ellis AG; Bohdanowicz M; Mashayekhi S; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Küster D; Siegels D; Schmitt J; Flohr C
    JAMA Dermatol; 2020 Jun; 156(6):659-667. PubMed ID: 32320001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study.
    Schneeweiss MC; Kim SC; Wyss R; Schneeweiss S; Merola JF
    J Am Acad Dermatol; 2021 Feb; 84(2):300-311. PubMed ID: 33038471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review.
    Zheng Y; Ding RL; Bu J
    Front Immunol; 2024; 15():1367099. PubMed ID: 38812522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current and upcoming treatments of adult atopic dermatitis].
    Lacour JP
    Ann Dermatol Venereol; 2017 Dec; 144 Suppl 5():VS29-VS37. PubMed ID: 29433635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
    Ariëns LFM; Gadkari A; van Os-Medendorp H; Ayyagari R; Terasawa E; Kuznik A; Chen Z; Bégo-Le Bagousse G; Lu Y; Rizova E; Graham NMH; Pirozzi G; De Bruin-Weller M; Eckert L
    Acta Derm Venereol; 2019 Sep; 99(10):851-857. PubMed ID: 31099402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on systemic therapies for atopic dermatitis.
    Denby KS; Beck LA
    Curr Opin Allergy Clin Immunol; 2012 Aug; 12(4):421-6. PubMed ID: 22622476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.
    Edwards SJ; Karner C; Jhita T; Barton S; Marceniuk G; Yiu ZZN; Wittmann M
    Health Technol Assess; 2024 Jan; 28(4):1-113. PubMed ID: 38343072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review.
    Roekevisch E; Spuls PI; Kuester D; Limpens J; Schmitt J
    J Allergy Clin Immunol; 2014 Feb; 133(2):429-38. PubMed ID: 24269258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug survival rates and reasons for drug discontinuation in patients with atopic dermatitis: a retrospective study of adult outpatients.
    Pino Lopez J; Kromer C; Herr R; Schmieder A; Bayerl C; Schaarschmidt ML
    Eur J Dermatol; 2021 Apr; 31(2):233-238. PubMed ID: 33871362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
    Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
    Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey.
    Totri CR; Eichenfield LF; Logan K; Proudfoot L; Schmitt J; Lara-Corrales I; Sugarman J; Tom W; Siegfried E; Cordoro K; Paller AS; Flohr C
    J Am Acad Dermatol; 2017 Feb; 76(2):281-285. PubMed ID: 27855965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
    Paller AS; Pinter A; Wine Lee L; Aschoff R; Zdybski J; Schnopp C; Praestgaard A; Bansal A; Shumel B; Prescilla R; Bastian M
    Adv Ther; 2024 Mar; 41(3):1046-1061. PubMed ID: 38194047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
    de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
    Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study.
    Paller AS; Siegfried EC; Simpson EL; Cork MJ; Sidbury R; Chen IH; Khokhar FA; Xiao J; Dubost-Brama A; Bansal A
    Am J Clin Dermatol; 2024 Jul; 25(4):655-668. PubMed ID: 38743155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population-based cohort study.
    Tsai SY; Gaffin JM; Hawryluk EB; Ruran HB; Bartnikas LM; Oyoshi MK; Schneider LC; Phipatanakul W; Ma KS
    Allergy; 2024 Oct; 79(10):2748-2758. PubMed ID: 39166365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.